Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

NZ sharemarket ends short week up 0.4%
Markets Market Close

NZ sharemarket ends short week up 0.4%

The S&P/NZX 50 Index closed at 12,902.19, up 57.6 points or 0.45%.

Graham Skellern 07 Feb 2025
Updated: Manawa shares sag with Contact deal odds
Finance

Updated: Manawa shares sag with Contact deal odds

Forsyth Barr analysts said chances are now 50/50. 

Pattrick Smellie 07 Feb 2025
Updated: Fletcher says no change to NZICC date
Markets

Updated: Fletcher says no change to NZICC date

Both SkyCity and Fletcher Building say they are not to blame for the NZICC delay.

Dileepa Fonseka 07 Feb 2025